Randomised controlled trial
OASIS-4
OASIS-4 investigators, NEJM 2025
- Participants
- 307
- Duration
- 64 weeks
- Comparator
- vs. placebo, alongside lifestyle intervention
Participants taking oral semaglutide 25 mg once daily lost up to ~16.6% of baseline body weight over 64 weeks versus ~2.7% on placebo in clinical-trial analyses (more conservative analysis methods estimated ~13.6%). Trial participants had BMI ≥ 30, or ≥ 27 with a weight-related comorbidity.

